drugset / Trial / NCT02356588

A Trial Evaluating the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for Post-Operative Pain After Abdominal Surgery

NCT02356588

Phase 3 Completed 161 enrolled Talphera, Inc
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to compare the efficacy and safety of the sublingual Sufentanil Tablet (ST) 30 mcg to the sublingual Placebo Tablet (PT) for the short-term management of moderate-to-severe acute post-operative pain in patients after abdominal surgery.

Timeline

Start
2015-02
Primary completion
2015-06
Completion
2015-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Sufentanil Other / unclassified 30 ug Subcutaneous

Indications

No indication recorded.